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Atherosclerosis is an important underlying cause of cardiovascular disease and death. 
According to the World Health Organization’s Global Burden of Disease Study, ischemic 
heart disease and stroke combined killed 12.9 million people in 2010, or one in four deaths 
worldwide. Ultrasound of the carotid arteries can be used to assess the burden of 
atherosclerosis by measurements of intima-media thickness (IMT) and total plaque area 
(TPA). Age, male gender, serum cholesterol, blood pressure and smoking are well known risk 
factors for atherosclerosis, while factors that may influence the progression of atherosclerosis 
have been less extensively studied. In the longitudinal population-based Tromsø Study, 
ultrasound assessment of carotid atherosclerosis was performed at in 1994-5 and repeated in 
2007-8. We found that age, male sex, total cholesterol, systolic blood pressure and smoking 
measured at baseline (1994-5) were associated with progression of TPA, whereas male sex, 
total cholesterol and systolic blood pressure (inverse) were predictors of progression of IMT. 
The metabolic syndrome, a cluster of metabolic and non-metabolic cardiovascular risk factors 
including impaired glucose tolerance, visceral adiposity, dyslipidemia, and hypertension, was 
not associated with progression of IMT or TPA in the total study population. Use of lipid-
lowering drugs had a protective effect against progression of carotid atherosclerosis, most 





Aterosklerose er en viktig underliggende årsak til kardiovaskulær (hjerte-kar) sykdom og død. 
I følge WHO forårsaket ischemisk hjertesykdom og hjerneslag tilsammen 12.9 millioner 
dødsfall i 2010, eller 1 av 4 dødsfall i verden. Ultralyd av hovedpulsårene på halsen (arteria 
carotis) kan brukes for å vurdere grad av aterosklerose i halskarene, ved bruk av å målinger av 
intima-media-tykkelse (IMT) og totalt plakkareal (TPA). Alder, mannlig kjønn, 
totalkolesterol, blodtrykk og røyking er velkjente risikofaktorer for aterosklerose. 
Risikofaktorer for progresjon av aterosklerose har i mindre grad vært studert. I den 
longitudinelle, populasjonsbaserte Tromsøundersøkelsen ble ultralydsmålinger av 
aterosklerose i halspulsåren (arteria carotis) målt i 1994-5 og gjentatt i 2007-8. Vi fant at 
alder, kjønn (mannlig), totalkolesterol, systolisk blodtrykk og røyking var assosiert med 
progresjon av TPA, mens kjønn (mann), totalkolesterol og systolisk blodtrykk (inverst) var 
uavhengige risikofaktorer for progresjon i IMT. Metabolsk syndrom, en ansamling av 
metabolske så vel som ikke-metabolske kardiovaskulære risikofaktorer som inkluderer nedsatt 
glukosetoleranse, økt livvidde, dyslipidemi og forhøyet blodtrykk, var ikke assosiert med 
progresjon av IMT aller TPA i studiepopulasjonen som helhet. Bruk av kolesterolsenkende 
medikamenter hadde en beskyttende effekt på progresjon av aterosklerose, og dette var mest 
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Atherosclerosis is the underlying cause of the majority of cardiovascular diseases (CVD) 
stroke and myocardial infarction.[1-3] Although incidence rates of both coronary heart 
disease and stroke have been declining in the Western world in the last decades,  mortality 
rates of ischemic heart disease and stroke are still increasing worldwide.[4, 5] Ischemic heart 
disease and stroke combined killed 12·9 million people in 2010, or one in four deaths 
worldwide. While the majority of cardiovascular disease events do not occur until middle age, 
atherosclerosis develops early in life.[6, 7] 
 
The artery wall consists of three layers; the intima, the media and the adventitia. The intima 
layer or tunica intima is the innermost towards the lumen of the vessel, and consists of 
endothelial cell and the internal basement membrane. The tunica media consists of smooth 
muscle cells, and the adventitial layer of connective tissue with elastic fibers and the external 
basement layer. Atherosclerosis is a condition in which the artery wall thickens as a result of 
accumulation of fatty deposits within the sub-intimal layer of the vessel wall.  Early 
atherosclerotic changes are fatty streaks or intimal thickening due to accumulation of smooth 
muscle cells. Intimal thickening may be the beginning of clinically significant lesions.[8] 
Biochemical, inflammatory and immune-modulating reactions which involve multiple cell 
types are initiated by the accumulation and oxidation of low-density proteins within the 
arterial wall. This leads eventually to the development of the raised atherosclerotic lesion – 






Figure 1. Development of atherosclerosis 
 
 
.[Image from Wikimedia Commons and Reproduced in accordance with the terms of the GNU free documentation license v1.2] 
 
Inflammation is modulated by macrophages that enter the arterial wall. They promote 
continued recruitment of immune cells and continued accumulation of LDL-cholesterol 
within the arterial wall. As a part of the immune response, T-lymphocytes enter the intima 
layer of the arterial wall and are activated following interaction with macrophages. T-cells 
secrete pro-inflammatory cytokines that contribute to additional atherosclerotic lesion 
progression. In response to secreted growth factors from activated immune cells, smooth 
muscle cells produce collagen, thus further promoting the inflammatory process. This results 
in a pathological thickening of the intima. As a necrotic core develops, continued activation 
and proliferation of smooth muscle cells contributes to a weakening of the fibrous cap, and 
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the risk of plaque rupture.[9] Certain sites are predisposed for atherosclerotic lesion 
formation. Most prone are areas with turbulent rather than laminar flow, such as branching 
points of arteries. Hence, plaques are much more common in the area of the carotid 
bifurcation than in the common carotid artery.[9] 
 
Various imaging modalities can be used to assess atherosclerosis in the arterial wall, where 
ultrasonography, magnetic resonance imaging (MRI), and computer tomography (CT) and are 
the most commonly used. Multislice CT is suited for detection of carotid plaques, as well as 
measurements of remaining lumen diameter. The resolution of a CT scan and the fact that it 
mainly highlights calcified tissue makes it not suited for detection of the different layers of the 
vessel wall,[10] and its use in population-based studies is limited by the use of contrast media 
and radiation exposure. MRI has a high spatial resolution, and the emergence of larger field 
strengths in MRI holds promise for better quality on imaging studies of small areas, such as 
the carotid vessel wall. However, the high associated costs limit the use of MRI in 
epidemiological trials. 
 
B-mode ultrasound is a simple tool, which enables us to visualize the vessel walls of the 
carotid artery at relatively low costs and without any risk. B-mode ultrasound has been used 
as imaging modality in the Tromsø Study, and will be thoroughly discussed later in this 
thesis.  Intravascular sonography offers information on both plaque burden and coronary 
atheroma volume as it depicts the arterial lumen and the arterial wall with high resolution. It is 
an invasive technique and as such not useful as a tool in large population based studies. 
Contrast-enhanced ultrasound is a novel and minimally invasive imaging technique that can 
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be used in assessing atherosclerotic lesions at risk of rupturing, but it has only been tested in 
limited clinical settings so far.[11] In addition, there is no radiation hazard associated with 
ultrasonography, which also makes it suited for repeated measurements. 
Carotid IMT is widely used as a measure of atherosclerosis. The intima-media thickness is 
depicted as the “double-line” pattern of the near- and far wall of the vessel, and represents the 
boundaries of the intima-media layers seen on artery specimens.[12] IMT increases by age 
and grows more rapidly in the presence of vascular risk factors. Earlier studies have found 
that IMT progresses approximately 0.015 mm annually.[13]  
 
Because atherosclerosis is so strongly related to both cardiovascular risk factors and CVD, it 
is widely used as a surrogate endpoint in studies on CVD. There is an ongoing debate as to 
whether IMT is a valid measurement of atherosclerosis,[14] or merely reflects hypertrophic 
adaptive response to high shear stress due to hypertension. Plaques are depicted on 
ultrasonography as focal protrusions into the lumen. As plaques develop at sites prone to 
atherosclerosis development, i.e. low shear stress and non-laminar turbulent flow,[15] as in 
the carotid bifurcation or internal carotid artery, they may be more representative of the real 
atherosclerotic process, compared to the IMT. Atherosclerotic plaque formation represents a 
stage of atherogenesis related to oxidation of lipids, infiltration and transmigration of 
lymphocytes and monocytes, inflammation and smooth muscle cell proliferation, and 
represent a more advanced atheromatous stage.[16] Plaque echogenicity is related to the 
contents of the plaque, where structures with higher echogenicity have a higher content of 
dense fibrous tissue and calcification, whereas structures with lower echogenicity 
(echolucency) have a higher content of lipids. Different scoring systems have been developed 
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for assessing the plaque burden. The San Daniele study used a plaque score based on degree 
of stenosis, echogenicity, texture (homogeneity) and surface characteristics in stroke risk 
prediction.[17] The Rotterdam Study used a plaque score based on the number of sites with 
ultrasonographically detected plaques in the carotid arteries.[18] The Northern Manhattan 
Study used maximum plaque thickness as a marker of plaque burden.[19] Spence and 
coworkers used total plaque area (TPA) and total plaque volume to assess plaque response on 
treatment in a clinical observational study between 1997 and 2007.[20] Barnett and coworkers 
found that the average change of plaque area during 2 years was double that of plaque 
thickness.[21] 
Risk factors for CVD and atherosclerosis have been studied through both population-based as 
well as clinical studies. Since the first publications from the Framingham study in the 1960s, 
it was shown that age, gender, cholesterol, hypertension, and smoking were the most 
important risk factors for coronary heart disease,[22] later often referred to as the traditional 
cardiovascular risk factors. As these risk factors do not explain all cardiovascular risk, efforts 
have been made to identifying additional biomarkers for CVD. High density lipoprotein 
(HDL) cholesterol was identified as a risk factor for myocardial infarction in 1977.[23] Later, 
several biomarkers have been suggested, such as markers of inflammation (CRP), diabetes 
mellitus and impaired glucose tolerance and others.[24] In the Emerging Risk Factors 
Collaboration, a collaborative study on over 1.1 million participants from 104 prospective 
population-based studies, elevated blood pressure, tobacco use, raised blood glucose, elevated 
fibrinogen, CRP, diabetes, physical inactivity and obesity/overweight were important risk 
factors for CVD.[25-28]   
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There are few studies on risk factors for progression of atherosclerosis. In the Rotterdam 
Study atherosclerosis was measured at multiple sites in the arterial tree and carotid 
atherosclerosis was measured as IMT in the common carotid artery. Plaque progression was 
calculated on the basis of a weighted plaque score ranging from 0-6, based on the number of 
sites a plaque was detected, divided by possible sites with a ultrasonic picture available.[18] 
The observation time was 6.5 years, and age, smoking, total cholesterol and systolic blood 
pressure and/or hypertension were strong, independent risk factors of progression of 
atherosclerosis. In the Atherosclerosis Risk in Community-study (ARIC), diabetes, current 
smoking, HDL-cholesterol levels and pulse pressure predicted IMT progression.[29] In a 
Finnish population based study on men only, age, LDL-cholesterol, smoking, blood leucocyte 
count and platelet aggregability were the strongest predictors of CCA-IMT progression.[30] 
The metabolic syndrome (MetS) is a cluster of metabolic and non-metabolic risk factors 
associated with increased risk of CVD and diabetes.[31-34] Although the concept of the 
metabolic syndrome has been widely investigated in basic, epidemiological and clinical 
research for several decades, there is still considerable uncertainty and controversy about the 
pathophysiology, its definition and prognostic relevance. The underlying pathophysiology is 
thought to be related to insulin resistance, reflected in the use of the term “insulin resistance 
syndrome”. Recent evidence indicates that central obesity is a precursor to the development of 
MetS.[35] Recently, the International Diabetes Federation (IDF), the American Heart 
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), the World Heart 
Federation, the International Atherosclerosis Society, and the International Association for the 
Study of Obesity joined forces to develop one unified definition of MetS.[28, 35] This 
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consensus defined the MetS as increased waist circumference (population- and country-
specific thresholds), increased fasting triglycerides levels (≥7.1 mmol/L) or drug treatment for 
elevated triglyceride glucose levels, reduced HDL-cholesterol level (<1.0 mmol/L in men, 
<1.3 mmol/L in women) or drug treatment for reduced HDL levels, increased blood pressure 
(systolic ≥130 and/or diastolic ≥85 mm Hg) or antihypertensive drug treatment in a patient 
with a history of hypertension, and increased fasting glucose (>5.5 mmol/L) or drug treatment 
of increased glucose levels.[28, 35]  
 
There is considerable doubt about whether the MetS predicts CVD better than the sum of its 
components. The majority of published reports have failed to prove the added value of MetS 
in CVD risk prediction.[36] However, a recent systematic review and meta-analysis of 37 
longitudinal studies showed that MetS was associated with future cardiovascular events and 
death with a relative risk (RR) of 1.78 (95% confidence interval (CI) 1.58- 2.00). The 
association remained after adjusting for traditional cardiovascular risk factors (RR 1.54, 95% 
CI 1.32 - 1.79).[37]   
The Cardiovascular Health Study was one of the first studies to show that increased IMT was 
associated with increased risk of myocardial infarction and stroke.[38] This has later been 
reproduced in numerous studies. A meta-analysis by Lorentz and coworkers in 2007 on IMT 
as predictor of myocardial infarction and stroke in general populations showed that an 
absolute carotid IMT difference of 0.1 mm increased the future risk for MI of 10-15% and for 
stroke 13-18%.[39] Measurements of IMT have later been included as a risk stratification tool 




 Whereas single measurements of IMT at baseline are consistently predictive of CVD, 
progression of IMT has been used as a surrogate endpoint for CVD outcomes in several 
clinical trials. However, it is unclear whether progression of IMT is associated with CVD 
endpoints.  In the Multi-Ethnic Study of Atherosclerosis (MESA) with 5082 participants and 
an observation time of 3.2 years, IMT progression was associated with incident stroke in a 
cohort free of prevalent CVD and atrial fibrillation at baseline.[42] In a systematic review and 
meta-regression analysis of IMT as a surrogate endpoint in RCTs of cardiovascular therapies, 
Goldberger et al found that less progression of IMT was associated with a lower likelihood of 
nonfatal MI in selected RCTs; however, these findings were inconsistent, suggesting caution 
in using IMT as a surrogate end point.[43] Costanzo et al showed that regression or slowed 
progression of carotid IMT did not reflect reduction in cardiovascular events in a meta-
analysis on 41 RCTs on different cardiovascular drug therapies.[44]   
 
In the last years, there has been increasing interest in the contribution of plaques in 
cardiovascular risk assessment.  In the Northern Manhattan Study, maximum carotid plaque 
thickness was associated with increased risk of vascular outcomes.[19]  A publication from 
the Tromsø Study (n=6584) showed that total plaque area in the carotid artery predicted 10 
years risk of ischemic stroke in both men and women, while IMT in the far wall of the 
common carotid artery was not associated with future ischemic stroke.[45] Another 
publication from the Tromsø study showed that carotid plaque area was a stronger predictor 
of first-ever MI than was IMT.[46] Spence et.al shoved that carotid plaque area and 
progression of carotid plaque identified patients with high cardiovascular risk.[47] The 
Atherosclerosis Risk In Communities (ARIC) study recently showed that adding plaque to 
IMT and traditional risk factors improved CHD risk prediction.[48] A recent review by Inaba 
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et al suggests that ultrasound assessment of carotid plaque compared to that of IMT have 
higher diagnostic accuracy for prediction of future myocardial infarction and detection of 
coronary artery disease.[49] 
 
The increasing interest in plaque measurements is reflected in the European guidelines for 
CVD prevention, where both IMT and plaque measurements are recommended in risk 
assessment in asymptomatic individuals at moderate risk. The latest Mannheim consensus on 
IMT as a surrogate endpoint of cardiovascular outcomes in clinical trials evaluating the 
efficacy of cardiovascular risk factor modification has acknowledged that incorporating 
carotid plaque measurements adds to the cardiovascular risk assessment.[50, 51]  
 
High cholesterol level is a strong risk factor for atherosclerosis, cardiovascular morbidity and 
mortality. Statins are the most important lipid-lowering drugs (LLD) in both primary and 
secondary prevention of CVD. Their main action is on reducing the LDL-cholesterol. Several 
randomized controlled trials have showed marked effect of statins in reducing risk of 
myocardial infarction and stroke.[52-57] A review of clinical studies found a significant 
beneficial effect of statins on IMT progression as well as stroke event rates.[58] Other meta-
analyses and RCTs have also shown that statins slow the progression of IMT.[59]  
Makris et al performed a meta-analysis on 17 prospective observation studies and 9 RCTs that 
had assessed the effect of LLD on plaque morphology (size and composition). These studies 
were small; the largest study included 149 and the smallest 8 participants.  Statin treatment 
was associated with a beneficial effect on plaque morphology, and slower progression, 
remodeling or even regression of the plaques.[60] In an RCT that compared rovustatin vs. 
placebo in 492 low risk patients, plaque progression was significantly lower in the statin 
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group.[61] In study on 654 patients who were randomized to 80 mg atorvastatin vs. 40 mg 
atorvastatin, more intensively treated patients had no change in atheroma burden, whereas 
patients with moderate dosage showed progression.[62]  
 
The generalizability of randomized controlled trials may sometimes be limited, and there is 
little knowledge on whether the effect of statins seen in RCTs applies to progression of 
atherosclerosis in the general population. In a prospective clinical study on 4378 patients who 
were referred to a stroke and atherosclerosis prevention clinic, a halt in plaque progression 
was observed after the implementation of more intensive medical therapy which included 













The main objective of this thesis was to study different risk factors that may influence 
progression of carotid atherosclerosis in a general population over 13 years. 
 
I. To assess the role of traditional cardiovascular risk factors in progression of carotid 
IMT and TPA, and to assess whether the association between risk factors and the 
markers of atherosclerosis were different for IMT and TPA. 
II. To study the impact of the metabolic syndrome and its components on progression of 
carotid atherosclerosis. 













The study population in all three papers consisted of attendees in the Tromsø Study who 
participated in the carotid ultrasound screenings in both the 4th and 6th survey.  The Tromsø 
Study cohort has been recruited among the inhabitants of the municipality of Tromsø, 
Norway, situated at 69° N. Among the current 70,000 inhabitants, about 60,000 people live in 
the city-like town-center, while the rest is scattered throughout the whole municipality. 
Tromsø is a center of education, research, administration and fishing-related activities. The 
population is growing and is dominated by Caucasians of mainly Norwegian origin, but also 
includes a Sami minority. The Tromsø population may be considered as representative of a 
Northern European, white, urban population.[63, 64] 
 
Since 1974, a total of 6 cross-sectional screening surveys (Tromsø 1-6, 1974-2008) have 
taken place, 6-7 years apart. The primary focus of the study is on cardiovascular disease, but 
over the years, the study has gradually expanded to include many other diseases and health 
related topics. Ultrasonography of the right carotid artery was initiated in the 4th survey 
(1994-1995), and was repeated in the 5th (2001-2002) and 6th (2007-2008) survey. All subjects 
were to give written consent to medical research. This consent can be withdrawn or reinstated 
at any point in time. Hence, the number of participants with valid medical consent can vary 
over time. In the 4th study, all participants who were between 55-74 years old and 5-10% 
samples of remaining birth cohorts were invited to a second visit (4-12 weeks after the first 
visit) with ultrasonography of the carotid artery. A total of 6727 (76 %) of eligible subjects 
attended the 2nd visit. The study participants in the three papers were all participants in the 
carotid ultrasound examination of the 4th (1994-1995; baseline) and the 6th (2007-2008; 
follow-up) survey, with a mean follow-up time of 13 years. During follow-up, 1515 persons 
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died and 468 persons moved out of the municipality. Of the remaining 4744 subjects who 
were invited to participate in the 6th survey, 2975 subjects (63 % of the eligible population, 
42 % of the baseline population) attended the follow-up carotid ultrasound examination, 
leaving 2975 subjects and these formed the basis for the study population of Paper 1. Later, 
one participant withdrew the consent to use the data for research purposes, leaving 2974 
subjects to be included in Paper 2 and Paper 3 (Figure 2).  Due to lack of information on 
deaths and emigration for the forty-one participants who had attended Tromsø 4, but who did 
not have valid written consent at the time the dataset was generated, we made erroneous 
assumptions about the numbers of participants who died or moved from Tromsø between 
baseline and follow-up. As a result of this, incorrect numbers of subjects who died, moved, 
and were invited to the second visit in Tromsø 6 were reported in Paper 2. The correct 
numbers are reported in Paper 3 and in Figure 2. A correction of the numbers reported in 
Paper 2 has been submitted to the journal Cardiovascular Diabetology.   
The Tromsø Study is approved by the Regional Committee for Medical and Health Research 










Figure 2. Description of the participation in the ultrasound examination in the 6th survey of 
the Tromsø Study (2007-2008, follow-up) in those who participated in the carotid ultrasound 
examination in the 4th survey (1994-1995, baseline). 
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High-resolution B-mode ultrasonography of the right carotid artery was at baseline performed 
with a duplex scanner (Acuson Xp10 128, ART-upgraded) equipped with a 7.5 MHz linear 
array transducer and at follow-up with a duplex scanner GE Vivid 7 with a linear 12 MHz 
transducer and followed the same scanning and reading procedures and reproducibility as 
published previously.[65-67] Different sonographers did the baseline and follow-up scanning, 
and to ensure equal and standardized examination techniques and measurement procedures, 
all sonographers completed a 2-month pre-study training protocol (Appendix V). 
 
A plaque was defined as a localised protrusion of the vessel wall into the lumen of at least 
50% compared to the adjacent IMT. Six locations of the carotid artery were examined for 
plaque presence; the far (FW) and near walls (NW) of the CCA, the bifurcation (bulb) and the 
ICA. If more than one plaque was present in a predefined location, the biggest plaque was 
chosen. The area of each plaque was outlined manually with automatic calculation of plaque 
area. The areas of all plaques were summarized to give the total plaque area (TPA). Plaque 
echogenicity was assessed as the standardized median of the gray scale distribution of each 
plaque (GSM). In subjects with more than one plaque, the GSM of the total plaque area was 
estimated as a weighted mean of the GSM value of each single plaque.  
 
Automated R-triggered measurement of IMT was performed in the far wall and near wall of 
the distal CCA,[66] as well as the far wall of the carotid bifurcation and was not limited to 
plaque-free segments. Final reading of both IMT and plaque data was done off line by the 
researchers. Measurements of IMT were analysed off line by a semi-automated computerized 
edge-detection program.[68] In Paper 1, only measurements from the FW of the distal CCA 
were used. To ensure that the CCA-FW-IMT measurements were done in plaque-free 
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segments only,[69] we excluded subjects with plaque in the distal CCA (n=145).[70] In 
Papers 2 and 3, we used the average of the mean IMT in three separate recordings from the 
three predefined locations in the analyses.  Progression of atherosclerosis (∆IMT and ∆TPA) 
was calculated subtracting values of IMT or TPA measurements in the 4th survey from the 
corresponding values in the 6th survey. 
 
Height and weight were measured in participants wearing light clothing and no footwear. 
BMI was calculated as weight (kg) divided by height (m ). Blood pressure was recorded three 
times at one-minute intervals after two minutes of seated resting with the use of an automatic 
device (Dinamap Vital Signs Monitor 1846 Criticon in Tromsø 4, and Dinamap ProCare 300 
Monitor in Tromsø 6) and by specially trained technicians. The mean of the last two 
recordings was used in the report. Analyses of non-fasting serum total cholesterol, HDL-
cholesterol and triglycerides were done by enzymatic colorimetric methods. In the 4th survey, 
lipid levels were measured twice with an interval of 4–12 weeks and the averages of these 
values were used in the analyses presented in this report. As serum low density lipoprotein 
(LDL) concentration was not measured in the 4th survey, we calculated LDL levels according 
to Friedewald’s formula: LDL-cholesterol = Total cholesterol – HDL-cholesterol – (0.45 x 
triglycerides) in subjects with triglyceride levels below 4.52 mmol/L. LDL was analyzed by 
homogeneous enzymatic colorimetric method in the 6th survey. Serum uric acid in Tromsø 4 
was measured by photometry with COBAS® instruments (Roche diagnostics, Switzerland) 
using an enzymatic colorimetric test, the uricase/PAP method. Glycosylated hemoglobin 
(HbA1C) levels were measured with a liquid chromatographic procedure. All analyses were 




Information on diabetes mellitus, use of insulin and/or oral anti-diabetic drugs, smoking 
habits (current daily smoking; yes/no), history of myocardial infarction, angina pectoris, 
stroke (yes/no) and treated hypertension (never/previous/current) were obtained from self-
administered questionnaires (Appendices II-IV). CVD was defined as self-reported prevalent 
angina pectoris and/or previous myocardial infarction and/or hemorrhagic or non-hemorrhagic 
stroke. Diabetes was defined as self-reported prevalent diabetes and/or use of anti-diabetic 
medication. 
 
All variables used in the prediction models in this thesis were obtained at the 4th survey in 
1994. An important exception is self-reported use of lipid-lowering drugs, where we in Paper 
3 used information obtained in the 4th, 5th and 6th surveys (see below, chapter 3.5). In Paper 2, 
we also used self-reported information on use of lipid-lowering, anti-platelet and 
antihypertensive drugs at baseline and follow-up as adjustment variables in supplementary 
analyses of the relationship between the metabolic syndrome and atherosclerosis. For lipid-
lowering and antihypertensive drugs, we used available information from questionnaires and 
from individual written lists of the brand names of all current medication that the participant 
had used the previous week (4th survey) or the preceding four weeks (6th survey). For anti-
platelet drugs, we used information from the brand name lists only, as the questionnaires did 
not include information on this item. In Paper 3, we performed additional analyses where 
participants with CVD at follow-up were excluded (Paper 3, page 859, Results section). We 





MetS was defined according to a modified version of the National Cholesterol Education 
Program Adult Treatment Panel III (NCEP, ATPIII).[34] According to this definition, the 
MetS is present when three or more of the following five criteria are fulfilled; abdominal 
obesity, hypertriglyceridemia, low HDL-cholesterol, hypertension, or elevated fasting 
glucose. Abdominal obesity was defined as waist circumference ≥ 102 cm in men and ≥ 88 
cm in women. Hypertriglyceridemia was defined as elevated triglycerides ≥ 150 mg/dL (1.7 
mmol/L) or self-reported lipid-lowering drug treatment. Low HDL cholesterol was defined 
as < 40 mg/dL (1.0 mmol/L) for men and < 50 mg/dL (1.30 mmol/L) for women or self-
reported lipid-lowering drug treatment. As fasting glucose was not measured in the Tromsø 
Study, HbA1c ≥ 6.1% and/or non-fasting plasma glucose ≥11.1 mmol/L and/or self-reported 
diabetes and/or use of anti-diabetic medication was defined as impaired glucose tolerance. 
Hypertension was defined as elevated systolic blood pressure ≥ 130 mmHg, or diastolic blood 
pressure≥ 85 mmHg, or self-reported current antihypertensive drug treatment. 
 
To assess the use of LLD over time, we used all available information on use of medication 
from the 4th, 5th and 6th surveys. Information was based on questionnaire data and self-
reported written lists of all current medication (Appendix II-IV). In the 4th survey (baseline), 
participants below the age of 70 were asked ‘Have you used cholesterol lowering drugs 
during the last 14 days?’. In the 5th survey in 2001-2002, all participants were asked about 
current or previous use of LLD (‘Do you use cholesterol lowering drugs?’, answer categories: 
currently/previously/never). Information on the use of LLD from the 5th survey was available 
for 2895 of the 2974 participants (97% of study population).  In the 6th survey, all participants 
were asked about current or previous use of LLD (‘Do you use, or have you used cholesterol 
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lowering drugs?’, answer categories: currently/previously/never) and their age when they 
started with LLD (‘If you use or have used cholesterol lowering drugs, how old were you the 
first time?’).  
 
Approximately 60% of those who answered that they used lipid-lowering drugs did answer 
the follow-up question on how old they were when they started. In addition, the participants 
were asked to write a list of the brand names of all current medication they had used the 
previous week (4th survey) or the preceding four weeks (5th and 6th survey) and/or bring the 
medication with them to the study center.  A trained technician at the study site checked the 
questionnaire and lists of brand names, and participants were asked to confirm if no use of 
medication was reported. Based on data from all three surveys, we calculated the duration of 
LLD use. Long-term use of LLD was defined as use either for more than 5 years (current age 
minus age at start), or use in at least two of the three surveys (each conducted more than 5 
years apart). Any-time use of LLD was defined as use in any of the three surveys, with the 
exclusion of long-term users. 
 
Stata SE 11 (StataCorp LP, College Station, TX, USA) and the SAS software, version 9, were 
used for all analyses. Differences between groups were analyzed with t-test or Wilcoxon rank 
sum tests (continuous variables) and χ ² (dichotomous variables). In Paper 3, within-group 
changes between baseline and follow-up were tested by paired (repeated) t-test for continuous 
variables and McNemar’s test for categorical variables. Within-group change is presented as 
unadjusted values.  Values are presented as means (SD), median (interquartile range) or 
numbers (%). TPA was square-root-transformed to approximate normal distribution. Change 
in IMT (∆IMT) and square-root-transformed TPA (∆TPA) was calculated subtracting the 
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values obtained in the 4th survey from the values from the 6th survey. The independent 
relationship between the different explanatory variables (cardiovascular risk factors, 
components of the metabolic syndrome and use of lipid lowering drugs) and the outcome 
variables (TPA, IMT, ∆TPA and ∆IMT) was assessed in multiple linear regression models, 
with two-sided p-values < 0.05 considered as statistically significant. In Paper 1, the main 
objective was to compare the effect of each independent variable on the outcome variables 
and to assess whether the effects were different for IMT and TPA. We therefore chose a 
complete case analysis and standardized all dependent and independent variables by use of z-
scores. In Paper 2 and 3, we allowed for missingness in both explanatory and response 
variables. In Paper 1 and 2, the explanatory variables were entered stepwise using the forward 
selection method. In Paper 2, the multivariable models included LDL cholesterol. 
Unfortunately, this was incorrectly typed as total cholesterol in two instances in the paper (the 
Statistical analysis section in Paper 2). A correction has been submitted to the journal. 
 
Interaction by age and sex was examined by adding cross-product terms between sex (or age) 
and each explanatory variable to the models. In Paper 2, there was significant interaction 
between sex and MetS in the IMT models, and all analyses were therefore stratified by sex. In 
Paper 1, the only consistent interaction was between sex and cardiovascular disease.  
In paper 3, we found no interaction between use of LLD and age or sex. We therefore chose 











Risk Factors for Progression of Carotid Intima-Media Thickness and Total Plaque Area.  
A 13-Year Follow-Up Study: The Tromsø Study. 
In this study we assessed cardiovascular risk factors of 13-years progression of carotid 
atherosclerosis in a middle-aged population (mean age at baseline 55.8 years for men and 56.6 
years for women). Mean yearly progression of IMT was 0.012 mm in men and 0.011 in 
women. Mean yearly progression of TPA was 0.82 mm2   in men and 0.56 mm2 in women. 
Plaque growth progressed more rapidly in both men and women after the age of 50, whereas 
the progression rate of IMT was constant over time.  
 
Sex, age, total cholesterol, systolic blood pressure and smoking were significant predictors of 
both follow-up IMT and TPA. BMI and HDL-cholesterol were predictors of follow-up IMT 
only. Use of LLD at baseline and prevalent CVD predicted follow-up TPA but not IMT. 
 Age, sex, total cholesterol, systolic blood pressure, smoking and use of LLD predicted 
progression of TPA, whereas sex, total cholesterol and systolic blood pressure predicted IMT 
progression. Systolic blood pressure was negatively associated IMT progression. The variance 
explained by traditional cardiovascular risk factors in general was modest, but somewhat 
greater for ΔTPA (summarized model R2 = 0.038) than for ΔIMT (summarized model R2 = 
0.010).   
The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The 
Tromsø Study. 
In this study, we assessed the associations between the MetS and the different components of 
the MetS (exposure variables) and follow-up levels and progression of IMT and TPA 
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(outcome variables). MetS was an independent predictor of follow-up IMT and TPA in 
women, and of follow-up IMT, but not TPA in men. MetS did not predict progression of IMT 
or TPA in the total cohort, but was associated with progression of IMT and TPA progression 
in subjects below 50 years of age. In analyses where the components of MetS were entered 
separately to the models, hypertension predicted follow-up IMT in both men and women and 
progression of TPA in women. Impaired glucose tolerance was associated with follow-up 
levels of IMT and TPA and with progression of IMT in men. Low HDL level predicted 
follow-up IMT in women, and hypertriglyceridemia was associated with follow-up IMT in 
men and women. Abdominal obesity was not significantly associated with IMT or TPA.  
 
Long-term use of lipid-lowering drugs slows progression of carotid atherosclerosis.  
The Tromsø Study 1994-2008 
In this study, we assessed whether long-term use and any-time use of LLD predicted 13-years 
progression of atherosclerosis. Of the 2974 participants, 443 persons were long-term users 
and 419 persons were any-time users of LLD. 
Both long-term use and any-time use of LLD protected against progression of carotid 
atherosclerosis. In long-term users, the beta coefficients (β) for ∆IMT and ∆TPA was -0.0387 
mm (p=0.0002) and -0.400mm  (p=0.006), respectively. In any-time users, the protective 
effect was weaker; β= -0.024 mm, (p=0.046) for ∆IMT and β= -0.318 mm2 (p=0.06 for 
∆TPA), indicating a dose-response relationship.  The estimates remained significant after 
exclusion of participants with CVD either at baseline and/or at follow-up (n=649). 
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A major strength of the Tromsø Study is the prospective design and the large sample size. The 
longitudinal design allows for repeated standardized measurements of carotid ultrasound 
variables as well as cardiovascular risk factors, relevant for adjustment. Our study is one of 
few studies that have assessed risk factors for progression of atherosclerosis measured as both 
IMT and plaque in the same individuals. 
 
Internal validity is defined as validity of inference for the source population of study subjects, 
or in other words, whether obtained results are representative or true for the population under 
study. Three types of error may threaten the internal validity: selection bias, information bias 
and confounding.  
 
Selection biases are distortions that occur as a result of procedures used to select subjects and 
from factors that influence study participation,[71] and the main concern is that 
between exposure and outcome among those selected for analysis differs from the
[72] Healthy persons could be more prone to volunteer in 
population studies. This is known as the healthy participant bias or volunteer/self-selection 
bias and may dilute true associations between risk factors and outcome by underestimating the 
true associations between exposure and outcome at follow up.  In another Norwegian 
population-based study (the HUNT Study), the prevalence of common chronic diseases 
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among non-participants was higher than in participants,[73] and it is likely that the same is 
true for the Tromsø Study. In prospective cohort studies, selection bias is usually not a major 
problem since information on exposure is obtained before the development of the outcome of 
interest. However, selection bias must be considered when the loss to follow-up is high, like 
in our study. 
 
Of the 6727 persons who participated at baseline, only 2975 attended the follow-up 
examination. Non-attendance at follow-up was due to migration in 468 and to death in 1515 
of the participants at baseline. Those who attended both surveys were healthier than those 
who were lost to follow-up. In Tromsø 4, 14.3% of all those who attended carotid 
ultrasonography had self-reported cardiovascular disease, compared to 19.5 % among those 
who attended ultrasonography in Tromsø 4 but not in Tromsø 6. In contrast, only 7.8% of 
those participating in both Tromsø 4 and Tromsø 6 had self-reported CVD. In Tromsø 4, 
4.6 % had self-reported diabetes, compared to 1.4% among those who attended both Tromsø 4 
and Tromsø 6. The total mortality was higher in the MetS group than the non-MetS group; 
28.8 vs 19.6%, p < 0.0001. It is possible that those with more severe baseline atherosclerosis 
and progression of atherosclerosis could be more prone to non-attendance due to 
cardiovascular disease or death and that the use of statins may have been more frequent in this 
group. We have no specific reason to assume that the relationship between risk factors and 
atherosclerosis progression would be differential in attendees and non-attendees, but this 
cannot be ruled out. The considerable loss to follow-up is likely to have affected the effect 




Information bias is the systematically inaccurate measurement of either the exposure or 
outcome variable. It can be non-differential (not dependent of the outcome variable) or 
differential (dependent of the outcome variable). In cohort studies, the information bias tends 
to be non-differential (not affecting any groups more than others), and this might dilute or 
underestimates the effect estimate.[71] Sources of error in estimation may be random (lack of 
precision) or systematic (inaccuracy, bias). The term accuracy refers to how close the 
measured values are to the true values, while precision refers to the magnitude of the 
differences between replicated measurements of the same material (reproducibility). Standard 
protocols and standard operational procedures were used to minimize errors. 
 
In our study, both the exposure variables and the outcome variables could have been 
misclassified. Important possible sources of information bias are the assessment of IMT and 
TPA (outcome variables) and the definition and classification of MetS and of use of LLD 
(exposure variables), which in the following will be discussed in more detail. 
 
Reproducibility of the ultrasound measurements 
Several measures were taken to standardize measurements and thereby avoid bias. 
Technicians underwent a two-month training program prior to study start, and standard 
operational procedures were used to minimize errors.  In order to estimate measurement 
variability, we conducted studies of between and within observer reproducibility in all 
surveys.[65-67] Ultrasound equipment was changed between the 5th and the 6th survey, and 
the inter-equipment variability was therefore also tested. 
Reproducibility of ultrasound measurements from Tromsø 4 and 5 has been described earlier  
and are summarized in Table 1 and 2.[65-67] In Tromsø 4, reproducibility for IMT 
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measurements was assessed by inviting 111 participants to a second ultrasound scan within 3 
weeks of the first scan. On each occasion three sonographers examined the subjects.[66]  
 
In the 6th survey, a consecutive sample of participants was selected for a reproducibility 
study. Two or three sonographers scanned seventy-six participants on the same day, and 71 of 
them were rescanned 1-2 weeks later. The sonographers had no knowledge of each other’s 
results, or results from previous examinations. The inter- and intra-observer reproducibility of 
IMT measurements was similar in Tromsø 4 and 6 (Table 1).  
 
 
Table 1. Inter-observer and intra-observer variability of pairwise measurements of mean* 
intima-media thickness in the 4th and 6th surveys of the Tromsø Study. 
 







Inter-observer     
   Tromsø 4  0.84 (0.28) -0.01       0.11 ±0.29 
   Tromsø 6 0.96 (0.21)  0.01 (-0.37,0.37)       0.08 ±0.21 
     
Intra-observer     
   Tromsø 4  0.84 (0.28) -0.01       0.10 ±0.33 
   Tromsø 6 0.97 (0.203)  0.02 (-0.018, 0.048)       0.08 (0.07) ±0.20 
*Average of the mean of three measurements in each of the three locations; the far and near wall of the common 




Reproducibility for plaque measurements and plaque detection was assessed in Tromsø 6 (in 
the same subjects as described above for IMT) and in combined data from Tromsø 4 and 5. 
There were 107 paired observations in the baseline study (Tromsø 4), and 83 in the follow-up 







Table 2. Inter-observer and intra-observer variability of pairwise plaque area measurements 











Inter-observer      
   Tromsø 4/5*  13.9 (9.0) -1.0 (-1.4,-0.6) 2.9 (3.4) ±8.6 
   Tromsø 6† 24.6 (15.0) -0.8 (-0.01,0.04) 6.1 (5.5) ±16.0 
     
Intra-observer     
  Tromsø 4/5 – observer 1 13.4 (7.9) 0.2 (-0.2, 0.7) 1.8 (2.5) ±6.1 
  Tromsø 4/5 – observer 2 13.8 (8.3) 0.0 (-9.5, 0.7) 2.1 (3.2) ±7.5 
  Tromsø 6† 23.8 (12.7) 9.6 (-2.6, 5.3) 6.7 (7.0) ± 18.9 
*Single plaque measurements.  
†Total plaque area measurements. 
 
 
The arithmetic differences between paired observations were plotted against their average to 
examine whether the differences were constant over the range of measurements (Figure 
3).[74] Any systematic differences between observers would result in the mean of the 
differences being significantly different from zero. The wider the scatter between the points in 
the direction of the y-axis, the worse will be the agreement. If the differences are normally 
distributed, 95 % of the differences will lie within a range of  1.96 SDs of the mean 
arithmetic difference, referred to as the limits of agreement. The mean or median absolute 
difference represents the typical magnitude, although not the “direction” of the differences. 
Reproducibility of plaque detection was analyzed with the use of the kappa statistic ( ).[75]   
 
The reproducibility of single plaque area measurements from Tromsø 4 and 5 and TPA 
measurements from Tromsø 6 are shown in Table 2.  As expected, the variability was higher 
for TPA than for single plaque measurements. More surprising was that the intra-observer 
reproducibility in Tromsø 6 was similar to or even slightly lower than the inter-observer 
reproducibility. This is also reflected in the kappa values for plaque detection, which was 0.65 




The variability study between the GE Vivid 7 and the Acuson XP10 was performed in 
January 2012 on 79 subjects, of whom 38 had ≥ 1 plaques. Subjects were examined with the 
Acuson XP10 first, and all examinations were performed by one person. All readings of IMT 
and plaques were done by a second person, blinded to the identity of the participants. The 
results are shown in Table 3. The variability shoved higher IMT values when measured with 
GE Vivid 7 compared to Acuson XP10, making it likely that the progression of IMT was 
overestimated due to change of machinery. There was no systematic bias between the 
ultrasound equipment for the TPA measurements. 
 
 
Table 3. Inter-equipment variability of pairwise measurements of mean* intima-media 
thickness and total plaque area in the 4th and 6th surveys of the Tromsø Study. 
 







Intima- media thickness 0.87 (0.13) 0.15 (0.13, 0.17) 0.15 ±0.16 
Total plaque area 24.1 (18.2) 2.4 (-0.5, 5.4) 6.5 (5.7) - 
*Average of the mean of three measurements in each of the three locations; the far and near wall of the common 




















Figure 3. Bland-Altman plots of inter- and intra-observer reproducibility of measurements of 
total plaque area (TPA) and intima media thickness (IMT).  
 
All panels (a-d) show the difference between pairwise measurements plotted against the 
average of pairwise measurements. Dotted lines denote the average difference between paired 
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Random measurement errors at baseline and follow-up tend to accumulate and hence 
attenuate the differences we seek to detect. Imprecision in the measurements of carotid 
atherosclerosis in our study is likely to have weakened the true relationship between risk 
factors and the measurements of atherosclerosis. Previous reproducibility data on IMT from 
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increasing IMT,[58] indicating that the estimates will be weaker in those with highest IMT 
levels.  
 
Another source of misclassification of an individual’s true atherosclerotic burden is the fact 
that only the right carotid artery was examined. Including the left carotid artery could have 
yielded better estimates of the actual atherosclerotic burden and stronger estimates of the 
relationships between risk factors and atherosclerosis. 
 
The carotid ultrasound protocol in Tromsø 4 was not originally set up to monitor change in 
IMT or TPA over time. Although several effort were undertaken to standardize 
measurements, further standardization could have reduced measurement errors.  Use of 
standardized uptake angles could have secured that participants were repeatedly scanned in 
the same angles as in former surveys. However, scanning at identical angles does not ensure 
that the areas with the most progression are captured. More intensive training and use of 
fewer sonographers could also have improved reproducibility. The use of multiple 
sonographers is prone to yield more imprecise results in longitudinal studies, but is difficult to 
avoid, especially when the examination volumes are large and the time span long.  
 
Definition of the metabolic syndrome 
One of the main components of the metabolic syndrome, impaired glucose tolerance, could 
not be assessed according to recommended criteria, as fasting glucose was not measured in 
the Tromsø Study. Instead, we defined HbA1c ≥6.1% and/or non-fasting plasma glucose 
≥11.1 mmol/L and/or self-reported diabetes and/or use of anti-diabetic medication as impaired 
glucose tolerance.  The 6.1% cutoff for HbA1c was based on previous studies.[76, 77] The 
use of HbA1c ≥6.1% as a substitute for fasting plasma glucose ≥5.6 mmol /L may result in 
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misclassification of subjects with impaired glucose tolerance. However, the HbA1C 6.1% 
cutoff is supported by a recent report from the Tromsø Study. [78] Those invited were all 
subjects without self-reported diabetes and with HbA1c in the range 5.8–6.9% and a random 
sample of approximately 200 subjects with HbA1c 5.3% and 5.4% and 100 subjects with 
HbA1c 5.5%, 5.6%, and 5.7%, respectively. Of the 4393 who were invited, 3476 participants 
completed an oral glucose tolerance test (OGTT).The best sensitivity (69.8%) and specificity 
(81.8%) for diabetes (n=199) were found at HbA1c 6.2%., while the best cut-off points for 
impaired fasting glucose (n=314) and impaired glucose tolerance (n=404) were found at 
HbA1c 5.9% and 6.0%, respectively.  
 
Another important source of error was the use of non-fasting lipid levels and the definition of 
hypertriglyceridemia. While HDL cholesterol is less influenced by non-fasting state, non-
fasting triglyceride levels are problematic because of the large variation in pre- and 
postprandial levels of triglycerides.[79] Furthermore, we included use of LLD (all types) in 
the definition of the triglyceridemia, while the standard criterion is use of drugs aimed 
specifically at reduction of triglycerides (fibrates and nicotinic acids).[31, 34] As our 
definition of MetS differs from the most common definitions, the results cannot be directly 
compared to other studies that have used standard definitions. 
 
Use of lipid-lowering drugs 
The use of LLD in our population increased considerably during the observation period, from 
1.6% in 1994, to 27% in 2008. Duration of LLD use was estimated on information obtained 
from both questionnaires as well as lists of current medication at three points in time. 
 Data on medication use is prone to recall bias. Although previous studies have shown that 
repeated self-reported use of drugs that are used regularly, such as statins, reflect chronic 
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exposure,[80, 81] participants may have failed to report use of LLD because they were not 
aware of the nature of the drug they were taking, or they could have forgotten to fill in all 
brand names in the medication lists. After the publication of Paper 3, we have validated the 
data on drug use obtained in Tromsø 6 against data from the Norwegian Prescription 
Database. The database was established in January 2004 and receives monthly data on drug 
prescriptions from all Norwegian pharmacies. Self-reported use of LLD in Tromsø 6 against 
data from the prescription database 6 months prior to the survey shows a kappa value of 0.94, 
sensitivity of 98% and specificity of 99% (Anne Elise Eggen, personal communication).  
 
Another form of bias relevant for pharmaco-epidemiological studies is immortal time bias. 
Immortal time refers to a period of follow-up during which the study outcome cannot 
occur.[82, 83] In our study, this bias is avoided by the fact that the outcome variable is 
progression of atherosclerosis over time, which can be measured equally in exposed and non-
exposed individuals.  
 
Change in cardiovascular risk factor levels over time 
 
In our studies, we used risk factor measured at baseline as exposure variables. This could be 
regarded as a source of misclassification, as risk factors levels are likely to change throughout 
the follow-up period. This was indeed shown for several risk factors in our study (Paper 3, 
Table 1). Risk factors measurements at several points point in time could have reduced 
measurement error and better reflected the true exposure levels over time. 
Confounding, unlike bias, is not an error in the study itself, but is the effect of additional 
variables that might be responsible for the observed observation. The confounder is an 
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independent factor for the outcome variable that is also associated or correlated with one or 
more of the exposure variables. In our studies, we have adjusted for known confounders such 
as age, sex and various cardiovascular risk factors. In Paper 3, we performed supplementary 
analyses where subjects with CVD were excluded. Nevertheless, we cannot exclude that the 
results may have been confounded by unknown variables that we were unable to account for.  
 
The external validity applies to the ability to generalize the results to other populations than 
the study population. For a study to hold external validity, it must be internally valid. The 
Population Registry was the source for the invitation issued. The age and sex distribution of 
the Tromsø Study reflects the Tromsø population in general and are not substantially different 
from other Western populations with regards to prevalence of CVD and risk factor levels. The 
IMT levels and plaque prevalence are comparable to those in other European and American 
populations. Hence, our results are likely to be applicable to similar Caucasian, Northern 
European populations.[63, 64] 
 
 
In all three papers included in this thesis, the outcome of interest was change in a continuous 
variable (IMT or TPA). We measured IMT and TPA at baseline and then again at follow-up. 
Both follow-up levels and a change score, calculated as the difference between the follow-up 
value and the baseline value, was used as outcome variables. In studies of change over time, it 
is important to consider the regression toward the mean (RTM) phenomenon in order to 
separate real change from the effect of natural variation. RTM describes the phenomenon 
where extreme measurements at one measurement point will tend to reverse against a less 
extreme value upon subsequent measurement. This occurs when values observed with random 
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error; i.e. a non-systematic variation in the observed values around a true population 
mean.[84, 85] The variation may be caused by random measurement error or random 
fluctuation in a subject. The magnitude of the regression effect can be determined from the 
correlation between pre-and post-measurements.[86] In general, within the same subject, 
extreme values (high or low) are likely to be followed by less extreme values closer to the 
subject’s true mean. The effect of RTM is not restricted to individual measurements, but also 
applies to the group level, and is especially important to take into consideration when 
comparisons are done in groups that are categorized on the basis on the initial values.[86, 87]  
 
Both the use of change scores (also referred to as growth score) and RTM have been subject 
to much debate within the scientific community. While some authors warn against use of 
change scores and find them unreliable,[88, 89]  others argue that difference scores are very 
reliable in situations where individual variations in true change exists.[90, 91] There is also an 
on-going debate how to deal with RTM in studies of change. The most widespread statistical 
technique is probably analysis of covariance (ANCOVA) with adjustment for baseline values 
of the outcome of interest.[87, 92] Many authors recommend adjustment for baseline values 
in all longitudinal studies of change to avoid the effect of any random differences in initial 
levels across the groups that are being compared.[86, 92].  
 
Other authors have argued against adjustment for baseline values. One of the strongest 
opponent against the view that RTM is unavoidable in longitudinal research, and that change 
scores are unreliable, is David Rogosa. Rogosa argues that rather than a law of nature, RTM is 
a statistical tautology arising from the use of standard deviation as a metric of change, and 
may not occur if a non-standardized metric is used.[93] Rogosa’s view has been supported by 
others who argue that although adjustment for baseline values of the dependent variable may 
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ameliorate certain biases, it introduces others that often will exceed the bias eliminated.[94, 
95] When the outcome variable is measured with error, inclusion of baseline values as a 
covariate may result in the finding of a relationship between the observed change and the 
explanatory variables even when no such association exist between the true outcome and the 
explanatory variables.[94, 96] Several alternative statistical techniques for the analysis of 
change have been proposed.[97, 98]  
 
In our studies, we chose not adjust for baseline values of IMT or TPA. This was in line with 
our previous choice in studies on change in ultrasound-assessed atherosclerosis based on the 
Tromsø Study.[99] An alternative approach could have been to adjust for both baseline and 
follow-up levels, or the mean of baseline and follow-up, as this variable is independent of the 
change score, which the baseline value is not. This approach is used in an individual data 
meta-analysis on predictors of change of IMT, the Individual progression of carotid intima 
media thickness as a surrogate of vascular risk (PROG-IMT) study, in which the Tromsø 
Study is one of the participating centers  (Simon G. Thompson, personal communication).  
However, although the baseline levels of TPA and IMT were not used to define groups for 
later comparison, adjustment for baseline levels to avoid RTM could have been considered 
appropriate due to differences in the baseline levels of atherosclerosis in subjects with and 
without MetS (Paper 2) and in users and non-users of LLD (Paper 3).  In Supplementary 
Tables 1 through 5, the analyses from Paper 1, 2, and 3 have been repeated in models with 
adjustment for baseline values in analyses with follow-up levels as outcome, and for baseline 
and the mean of baseline and follow-up values in analysis with the change score as outcome. 
In addition, the analyses originally presented in Paper 2 were done with variables 
standardized by use of z-scores for better to be able to compare the strength impact of the 
variables on the outcome. The results show substantial differences depending on the choice of 
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model. Overall, adjustment for baseline values in analyses with follow-up levels as the 
outcome variable tended to weaken the estimates originally presented in Paper 1 
(Supplementary Table 1). The explained variance increased and was mostly explained by the 
baseline values of IMT and TPA, respectively. In analyses of change scores as dependent 
variable, adjustment for baseline values strengthened the estimates, while the mean of 
baseline and follow-up values weakened the estimates. The overall explained variance 
increased in both models.  
 
Similarly, the analyses in Paper 2 were substantially influenced by choice of model. In 
analyses with MetS, age, LDL cholesterol, smoking and baseline IMT /TPA as predictor 
variables and follow-up levels of IMT/TPA as outcome, the baseline levels explained most of 
the variance while the other estimates were weakened. As opposed to this, adjustment for 
baseline variables tended to strengthen the estimates in analyses with change scores, and in 
these analyses, MetS was a significant predictor of change in both IMT and TPA in men, but 
not in women. Adjustment for mean of baseline and follow-up did not influence the 
relationship between MetS and the outcome variables. Analyses where each component of 
MetS was entered as separate variables showed similar results as described for MetS, with a 
tendency toward weakening of the estimates. Age became negatively associated with change 
in IMT after adjustment for mean of baseline and follow-up values, and the same did LDL 
cholesterol in men and hypertension in women. These associations are counter-intuitive and 
difficult to explain, and seem to be a result of this particular model.     
 
In Paper 3, the relationship between use of LLD and progression of atherosclerosis was no 
longer significant after adjustment for baseline values, while the estimates were strengthened 




The tables illustrate the complexity of analyses of change and that the choice of model has 
substantial impact on the obtained results. It is recommended that researchers should decide 
upon the analytical strategy prior to performing the statistical analyses, and thereafter adhere 
to the initial analysis plan.[92] Therefore, in the further discussion of the results in this thesis, 
I have chosen to refer to the original analyses (as presented in the papers). 
 
We found that age, male sex, total cholesterol, HDL-cholesterol (inversely), systolic blood 
pressure, body mass index and smoking predicted follow-up levels of IMT. In contrast, 
systolic blood pressure was negatively associated with progression of IMT. These apparently 
conflicting results are however partly supported by previous studies. In the Rotterdam Study, 
systolic blood pressure was a predictor of severe progression of IMT, but not for mild or 
moderate progression.[18] In the ARIC study, hypertension was not an independent risk 
factor for yearly progression of IMT.[29] Salonen and Salonen did not find an association 
between hypertension or current blood pressure level and a two year progression of IMT.[30] 
One possible explanation might be that there is larger within-person variance of progression 
of IMT than of cross-sectional measurements, and this can result in stronger estimates for 
cross-sectional analyses compared to longitudinal studies with several measurements.  
 
The annual progression of IMT was 0.012mm in men and 0.011mm in women, which is 
higher than the annual progression of 0.009 mm in the ARIC cohort.[29]  As discussed above, 
we may have overestimated the progression of IMT due to change of equipment. However, in 
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a pooled analysis on annual progression of IMT in control subjects who participated in RCTs, 
the annual change of IMT was 0.015 mm.[13]  
 
We found that the progression rate of TPA increased by age, whereas progression of IMT was 
constant across age groups. Also, the explained variance of CVD risk factors on IMT and 
TPA progression was low to moderate; 10% for ∆IMT, and 38% for ∆TPA. This might be due 
to different qualitative aspects of these two measures of atherosclerosis, with medial 
thickening increasing at a more constant level, while plaque size increases more rapidly over 
the years. There is an ongoing debate as to what ultrasonographic measures most correctly 
describe the atherosclerotic process.[47, 49, 100-103] Plaques and IMT are highly correlated, 
but may not reflect the same biological aspects of atherogenesis, and these entities may have 
different relations to cardiovascular risk factors as well as to clinical vascular disease.  IMT 
mainly represents hypertensive medial hypertrophy, whereas TPA represents the intimal 
thickening constituting atherosclerosis.[104] TPA has been stronger correlated with 
traditional risk factors than IMT in previous studies.[14, 101]  
 
The IMT is a small structure, only fractions of a millimeter and the resolution of the B-mode 
ultrasonography is below the quantities being measured. This makes the method less suitable 
for repeated measurements, as random measurements errors at baseline and follow-up are 
accumulated, thus attenuating the differences we aim to detect.[105] The TPA measures a 
larger quantity, and may thus being more robust against measurement errors.  This may be 
one of the reasons for lack of association between progression of IMT and cardiovascular 




There was significant interaction between cardiovascular disease and sex for all outcome 
variables. In forward stepwise multivariable models in women, CVD was negatively 
associated with follow-up levels of IMT (standardized β= -0.089, p=0.006) and with change 
in TPA (standardized β= -0.074, p=0.009), while there was no association between CVD and 
change in IMT or follow-up levels of TPA. In men, CVD was positively associated with 
follow-up levels of TPA in men (standardized β=0.077, p=0.002), but not with follow-up 
levels of IMT or progression of IMT or TPA. There was no interaction between 
cardiovascular risk factors and age.  
 
We found that the MetS was an independent predictor of follow-up levels of IMT and TPA, 
for men, and for IMT in women. There was no overall association between MetS and 
progression of IMT and TPA. Among the components of the MetS, hypertension predicted 
TPA progression in women and impaired glucose tolerance predicted IMT progression in 
men.  
 
There is an ongoing debate as to whether the MetS is a better predictor of cardiovascular 
disease than the sum of its components. Hypertension was the component of MetS most 
consistently associated with follow-up levels of IMT and TPA among men and women. 
Hypertension was also associated with progression of TPA in women. Impaired glucose 
tolerance (IGT) was associated with follow-up levels and progression of IMT in men only. 
The underlying pathophysiology of MetS is thought to be related to IGT, and associations 





Previous cross-sectional studies have found increasing IMT in subjects with MetS.[108-110] 
Few studies have assessed the relationship between MetS and progression of IMT. The 
European Lacidipine Study on Atherosclerosis (ELSA) found that progression of IMT was 
slightly higher in persons with MetS, but this association was not significant after adjustment 
for cardiovascular risk factors.[111] 
 
In our study, MetS was associated with progression of atherosclerosis in subjects below 50 
years of age. This is in line with the findings in a Finnish study where progression of IMT was 
associated with MetS in subjects aged 27-37 years.[112] As the atherosclerotic process 
accelerates through the 4th and 5th decade, this might imply that the MetS is more important as 
a risk factor in the early stages of the atherosclerotic process. Caution must be taken to this 
hypothesis, as longitudinal data on this field are scarce.  
 
In a cross-sectional study from the multiethnic Northern Manhattan Study (NOMAS), MetS 
and the number of MetS components was significantly associated with plaque presence.[113] 
The proportion of subjects with MetS was high in NOMAS (49%). The NOMAS study also 
showed a significant association between MetS and arterial stiffness, independent of the 
presence of carotid plaque and intima media thickness.[114] In the Bruneck Study, persons 
with MetS had higher rates of progression of carotid atherosclerosis, measured as formation 
of new plaques and carotid stenosis.[115] We cannot exclude that the lack of overall 
association between MetS and atherosclerosis progression in our study may be due to 
imprecise measurements of both the predictor and the outcome variables, as discussed above. 
Our definition of MetS may have led to some misclassification. Imprecision in measurement 
of outcome variables of progression may be due to accumulation of random measurement 
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error at baseline and follow-up, and this can attenuate the differences and inability to detect a 
true relationship between MetS and change in carotid atherosclerosis.  
 
Supplemental Tables 3 and 4 show the results of the multivariable-adjusted analyses in Paper 
2 repeated with all variables standardized by use of z-scores. These show that for both men 
and women, age was the strongest predictor of follow-up levels of IMT and TPA. Of the 
components of the MetS, hypertension is also in men by far the strongest predictor of follow-
up levels of IMT and TPA. For ∆IMT, neither the Mets nor its components have significant 
associations in neither men nor women. Hypertension was significantly associated with ∆TPA 
in men. 
 
We found that MetS predicted progression of IMT and TPA in men below 50 years of age, 
but not in the total cohort. However, we found no significant interaction between age and 
MetS, and in retrospect, we find that we may have put too much emphasis on this finding as 
presented in the paper. 
 
 
We found that long term as well as any-time use of LLD protected against progression of IMT 
and TPA. Similar results have been shown in RCTs [54, 116, 117] and clinical patient 
series.[20, 118] Our study indicates that this also applies to subjects belonging to the general 
population. As statins are related to slower progression of atherosclerosis, it has been assumed 
that the protective effect of statins on CVD is at least partly mediated through the effect on 
atherosclerosis. In a meta-analysis of 28 RCTs with 15 598 patients, Goldberger et al. found 
that change in IMT was a significant predictor for myocardial infarction. Surprisingly, and as 
acknowledged by the authors, counter-intuitively, no significant relationship was found 
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between mean change in IMT and nonfatal myocardial infarction when the analysis was 
limited to RCTs which evaluated statin therapy. The authors conclude that this may implicate 
that the protective effect of statins on cardiovascular disease is not mediated through 
IMT.[43]   
 
The protective effect of statins was present also when we excluded subjects with prevalent 
CVD at baseline and/or follow-up. The benefit of taking statins in primary CVD prevention 
has been much debated.[119] A recent Cochrane update on statins for the primary prevention 
of cardiovascular disease, showed reductions in all-cause mortality, major vascular events and 
revascularization among people without evidence of CVD treated with statins, and without 
any excess of adverse events.[120, 121]  The results of our study should not be taken in favor 
of use of statins in primary prevention, as no analyses of net positive effects (whether the 
beneficial effects of statins outweighed the possible detrimental effects) nor of cost-
effectiveness could be done.  
 
 
In the Results section in Paper 3, the change in IMT and square-root-transformed TPA levels 
in non-users and long-term users of LLD was unintentionally mixed up. An erratum has been 






We found that progression of TPA was independently predicted by age, sex, total cholesterol, 
systolic blood pressure and smoking. Total cholesterol, sex and systolic blood pressure 
(inversely) were associated with IMT progression. 
 
Plaque growth progressed more rapidly after the age of 50, while the progression rate of IMT 
was constant over time. 
 
MetS was an independent predictor of follow-up IMT and TPA in men and of IMT in women. 
MetS was not an independent predictor of progression of TPA and IMT in the total cohort.  
 
Use of LLD had a protective effect on both TPA and IMT progression, most pronounced in 
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5.3 (Municipality) (County) (Country)
9.3 (Business) 9.4 (Occupation) 14.7 (Mark)






Fibromyalgia/chronic pain syndrome ......
Psychological problems for which you  
have sought help  ............................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage .........
2.1 Have you suffered from pain and/or stiffness in 
muscles and joints during the last 4 weeks?
5.1 How long altogether have you lived in the county?
5.2 How long altogether have you lived in the municipality?
5.3 Where did you live most of the time before the age of 16?
Same municipality ....
Another municipality
in the county .............. Which one:
Another county in Norway Which one:
Outside Norway ........ Country::
5.4 Have you moved within the last five years?
No Yes, one time Yes, more than once
1           2       3
NoYes
1.1 What is your current state of health? 
Poor Not so good Good Very good
1                  2               3           4
1.4 Do you get pain or discomfort in the chest when:
Walking up hills, stairs or walking fast on level ground?
1.6 If you stop, does the pain disappear within
10 minutes? ...........................................................
1.7 Can such pain occur even if you are at rest?........
1.5 If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?









Upper part of your back... 
Lumbar region .................












2.2 Have you ever had:
Fracture in the wrist/forearm  ...................
Hip fracture?..............................................
1. YOUR OWN HEALTH 3. OTHER COMPLAINTS
4. USE OF HEALTH SERVICES
5. CHILDHOOD/YOUTH AND AFFILIATION
6. BODY WEIGHT
2. MUSCULAR AND SKELETAL COMPLAINTS
3.1 Below is a list of various problems. Have you experienced 
any of this during the last week (including today)?
Sudden fear without reason ....................
Felt afraid or anxious ..............................
Faintness or dizziness ............................
Felt tense or upset ..................................
Tend to blame yourself ...........................
Sleeping problems ..................................
Depressed, sad ......................................
Feeling of being useless, worthless ........
Feeling that everything is a struggle ......










1             2            3           4
4.1 How many times in the last 12 months have you been to/used:
General practitioner (GP) .......................
Medical officer at work ...........................















6.1 Estimate your body weight when you
were 25 years old: kg
1.3 Have you noticed attacks of sudden changes in  









7. FOOD AND BEVERAGES 8. SMOKING
9. EDUCATION AND WORK
7.1 How often do you usually eat these foods?
7.2 What type of fat do you usually use? 
7.3 Do you use the following dietary 
supplements:
8.1 How many hours a day do you normally spend
in smoke-filled rooms?
8.2 Did any of the adults smoke at home 
while you were growing up? .................................
8.3 Do you currently, or did you previously live
together with a daily smoker after your
20th birthday? 
8.4 Do you/did you smoke daily? ..................
If NEVER: Go to question 9 : (EDUCATION AND WORK)
8.5 If you smoke daily now, do you smoke:
8.6 If you previously smoked daily, how
long is it since you quit?










Cod liver oil, fish oil capsules ..............
Vitamins and/or mineral supplements?
7.4 How much of  the following do you usually drink?
7.5 Do you usually drink soft drink: with sugar 1 without sugar      2
7.6 How many cups of coffee and tea do you drink daily?
7.7 Approximately how often have you during the last year 
consumed alcohol?
7.8 When you drink alcohol, how many
glasses or drinks do you normally drink?
7.9 Approximately how many times during the last
year have you consumed alcohol equivalent to




















Yes, daily Sometimes No
1               2             3              4              5             6
Full milk, full-fat curdled milk, 
yoghurt ..................................
Semi-skimmed milk, semi-skimmed 
curdled milk,low-fat yoghurt ......
Skimmed milk, skimmed 
curdled milk ..............................
Extra semi-skimmed milk ......
Juice .....................................
Water ....................................
Mineral water (e.g. Farris, 
Ramløsa etc)
Cola-containing soft drink .....














1 2            3            4            5
Filtered coffee ..........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1              2        3 4
5               6        7 8
7.10 When you drink, do you normally drink:
Beer Wine Spirits 
9.1 How many years of education
have you completed? 
9.2 Do you currently have paid work?
9.3 Describe the activity at the workplace  where 
you had paid work for the longest period in the
last 12 months. 
Business:
9.4 Which occupation/title have or had you at this workplace?
Occupation:
9.5 In your main occupation, do you work as self-employed, 
as an employee or family member without regular salary?
9.6 Do you believe that you are in danger of losing 
your current work or income within the next 
two years? ...........................................................
9.7 Do you receive any of the following benefits?
Yes No





Sickness benefit (are on sick leave) .......................
Old age pension, early retirement (AFP) or
survivor pension ..................................................... 
Rehabilitation/reintegration benefit .........................
Disability pension (full or partial) .............................
Unemployment benefits during unemployment .......
Social welfare benefits ............................................
Transition benefit for single parents ........................
How many cigarettes do you or did you
normally smoke per day? 
How old were you when you began
daily smoking?
How many years in all have you
smoked daily? 
Yes       No
Yes No
Yes, full-time Yes, part-time No1                    2                  3






Blood pressure lowering drugs ...................
Cholesterol-lowering drugs .........................
Reading, watching TV or 
other sedentary activity? ......................................... .........
Walking, cycling or other forms of  
exercise at least 4 hours a week? .....................................
Participation in recreational sports, heavy gardening, etc.?
Participation in hard training or sports competitions, 
regularly several times a week? ........................................
None Less than 1 1-2 3 or more
10.1 How has your physical activity in leisure time been 
during this last year?
11.3 How much interest do people show for what you do?
11.4 How many associations, sport clubs,groups, religious
        communities or similar do you take part in?  
11.5 Do you feel that you can influence what happening
in your local community where you live? 
12.1 Have one or more of your parents or siblings
had a heart attack (heart wound) or
angina pectoris (heart cramp)? ..........................
12.2 Tick for the relatives who have or have
had any of the illnesses:
Cerebral stroke or 
brain haemorrhage .......
Heart attack




12.3 If any relatives have diabetes, at what age did they get
diabetes (if for e.g. many siblings, consider the one who 
got it earliest in life):
11.2 How many good friends do you have?
10.2 Describe exercise and physical exertion in your leisure time.
If your activity varies much e.g. between summer and winter, 
then give an average. The question refers only to the last year.
1 2 3                 4
10. EXERCISE AND PHYSICAL ACTIVITY
11. FAMILY AND FRIENDS
12. ILLNESS IN THE FAMILY
13. USE OF MEDICINES
14. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
13.1 Do you use:
14.1 How old were you when you  
started menstruating?
14.2 If you no longer menstruating, how old were
you when you stopped menstruating?
14.3 Are you pregnant at the moment?
14.4 How many children have you 
        given birth to?
14.5 Do you use, or have you ever used?
13.2 How often have you during the last 4 weeks used
the following medicines?
13.3 For those medicines you have checked in points 13.1 and 























Mother's age Father's age Brother's age Sister's age Child's age
Father Brother Sister Child
None
of these
Yes, some Yes, a little No
Never 
tried









Other prescription medicines ...
Oral contraceptive pills/mini pill/
contraceptive injection ................
Hormonal intrauterine device (IUD)
Estrogen 
Estrogen 
State the name and the reason that you are taking/have taken











Name of the medicine: Reason for use of Up to 1 year
the medicine 1 year or more
How long have you
used the medicine
Yes No Uncertain Above fertileage 






























but not now Never
14.6 If you use/have used prescription estrogen:
How long have you used it?
14.7 If you use contraceptive pills, mini pill, contraceptive 
injection, hormonal IUD or estrogen, what brand do you use?
1 2 3 4
1          2                    3        4                 5






















































PROCEDURES FOR MEASUREMENTS OF INTIMA-MEDIA THICKNESS AND 
RECORDING AND MEASUREMENTS OF PLAQUE OF THE RIGHT CAROTID 
ARTERY.  THE TROMSØ-STUDY 1994/95 AND 2001  
 
by Oddmund Joakimsen 




1. The Acuson ultrasound instrument is switched on. 
 
2. A videocassette is inserted in the video recorder. 
 
3. Check that the videotape has been wound to the right position, do not overwrite previous 
recordings. The videocassette should not be removed from the recorder during the day. 
    
4. Cassettes are marked with serial numbers, uneven numbers for Acuson I, even numbers for 
Acuson II.  
 
5. The initials and the identity numbers of the participant and the sonographer number (Einar 
= 1, Stein Harald = 2, Technician = 3) are written on each ultrasound image recorded. 
Labels with the ID-number of the participants are attached to the registration form, in 
which all ultrasound data obtained from the participants are filled (plaque localization, 
size, “missing measures” coding, etc.). 
 
6. A RES-field, appropriately adjusted to a maximum width of the screen and a depth of a 
little more than the preset size (> 2 cm) is positioned on the screen (This makes off-line 
calibration easier).  
 
7. The subject is examined in a supine position with the head slightly rotated to the left (15-
45 degrees). ECG-pads are attached to both arms and the right leg (or abdomen) (lead I), 
and the right carotid is insonated by a 7.5 MHz ultrasound transducer.  
 
8.  The examination starts with identification of crossectional B-mode images of the carotid 
artery, and, if necessary for identifying purposes in combination with colour-Doppler 
and/or pulsed wave Doppler 5 MHz. The examination starts caudally in the neck, normally 
just above the clavicle, then moving the probe upstream with simultaneous rotation 
movements to search for plaques also at the circumference of the vessel. Thus, the carotid 
artery is searched from the proximal part of the common carotid artery (CCA), upstream to 
the bifurcation (BULB), and as far up in the internal carotid artery (ICA) as technically 
possible. A PLAQUE is defined as a presumed atherosclerotic lesion of the intima layer of 
the vessel wall presenting a focal protrusion of more than 50% of the intima-media 
thickness (IMT) of the surrounding vessel wall, often with deviating echogenicity 
compared to other part of the artery wall. Whether a plaque is present or not is a decision 
taken by the sonographer during the examination. Live crossectional imaging of the whole 




9. An ultrasound examination sequence is then performed in the TRIPLEX -mode (i.e.,     
  combination of B-mode examination, pulsed wave Doppler, colour Doppler) 3-4 cm     
  proximally to the bifurcation and upstream 2-3 cm distally the bifurcation in the ICA.    
  The objective of this part of the examination is to look for stenotic areas along the artery   
  that causes hemodynamic disturbances. However, if plaques later during the B-mode  
  scanning procedure are found suspicious of a hemodynamic significant stenosis, a new  
  TRIPLEX examination is performed to re-evaluate the flow conditions. A LIVE    
  TRIPLEX-sequence of the relevant part of the carotid artery is recorded on the videotape   
  if a stenosis is suspected. 
 
10. B-mode longitudinal ultrasound scanning of the carotid artery is then performed. To get 
an optimal topographic reference, the examination is starting as proximally as possible in 
CCA. The probe is then moving upstream with simultaneous rotating movements to look 
for plaques in all segments, both the near and the far wall. If a plaque is found, a frozen 
image of the vessel-wall is taken – either directly by using the “FREEZE”- key, or by 
choosing on of the pictures from the cine-loop. It is important that the plaque is presented 
as distinctly as possible and after the guidelines according to elementary ultrasound 
principles such as vertical propagation of the ultrasound beam, presentation of the plaque 
in the full diameter of the vessel and not in chord, not cutting the plaque skew causing a 
falsely too large thickness of the plaque. To ensure the quality of plaque registration, 
some technical points may be of help: The plaque should be “attached” at its both ends to 
the typical double-lined intima-media structures visible on the B-mode image, and these 
double-lined structures should best be visible both in the near and the far wall at the same 
time. When the echogenicity obtained is as high as possible (as bright as possible), this is 
an indication that the ultrasound waves have cut the plaque optimally. An electronic 
calliper is put on the top of the plaque (at the interface between the surface of the plaque 
and the vessel lumen), and another calliper in the presumed transition zone between the 
media and the adventitia layer. The distance between the callipers is the thickness of the 
plaque, and that value is put on the registration form in the appropriate box. The B-mode 
image of the plaque is identified correctly by marking on the display what has been 
found, and where: PLAQUE ICA FW (a plaque in the far wall of the internal carotid 
artery), PLAQUE BULB NW (a plaque in the near wall of the bifurcation), etc. A short 
recording of approximately 5 sec. is videotaped. If more than one plaque is present at a 
site (e.g., in the far wall of ICA), the largest is chosen and recorded. 
 After identifying and recording of plaques, imaging procedures to get optimal 
measures of IMT from CCA and the BULB are performed. Optimal images are available 
when distinct double contours of the vessel wall typical for the intima-media complex can 
be seen. It is important that the longitudinal axis of the insonated vessel wall is 
perpendicular to the ultrasound beam direction. To avoid falsely too thick intima-media 
layer, the IMT should be measured in the full diameter of the artery and not in a chord. 
When satisfactory images are achieved, R-wave triggered IMT-registrations are recorded 
on a cine-loop containing more than 20 images. Afterwards, the images stored in the cine-
loop are scrutinized and 3 of most representative images, and each at least 10 images 
apart, are selected for recording on the videotape.  
 Regarding IMT measurements in the BULB, the start of the BULB is first identified 
and then marked with an arrow. This is the point where the parallel walls of the CCA are 
starting to diverge. If the probe throughout the recording process in the cine-loop has 
changed position, the placing of the arrow marker must be adjusted accordingly. It is 
important to underline that it is the sonographer who places the marker and not the off-
 3 
line reader of the IMT-measurements. The arrow setting has to be as precise as possible, 
particularly when a plaque is located in the border zone between BULB and CCA to 
avoid over-or underestimating of IMT.  
       The target site for IMT measurements of BULB is the 1 cm area from the start 
of the BULB and upstream, distally. If only a part of this distance is measurable, a 
recording may, however, be performed on this shorter distance if the live sequence shows 
that this part of the vessel wall is representative of the rest of the 1 cm area. This shorter, 
measurable distance is marked with an electronic star. The 3 chosen images are marked 
BULB1, BULB2 and BULB3 and recorded on the videotape.  If no measurable image is 
possible to obtain, an image from the BULB is still recorded and marked MB, i.e., 
“missing bulb”. IMT measurements from the near wall of the BULB are not performed. 
 
  
11. Then a B-mode scanning of the CCA is performed, starting at the BULB and downstream     
as far as possible. Registration and measurements of plaque are done in the same way as 
mentioned above. The images with plaques are marked PLAQUE CCA FW and 
PLAQUE CCA NW, video recording is performed of both the live sequence and the 
frozen, marked images. R-wave triggered CCA IMT-registrations are recorded and the 3 
optimal images are chosen from the cine-loop as described in paragraph 10. It is 
important to get representative images also from the near wall since IMT-measurements 
from the CCA-NW will be done off-line. The arrow-marker is placed in the same position 
as for the BULB measurements. The target site for IMT measurements of CCA is the 1 
cm area from the start of the BULB and 1 cm downstream, proximally. The three images 
chosen to be recorded are marked CCA1, CCA2 and CCA3. If no measurable image is 
possible to obtain, an image from the CCA is still recorded and marked MC (”missing 
CCA”). All measurements on the far wall refer to the so-called “leading edge” principle 
(or “upper demarcation line”). These structures are not being different in thickness when 
the emitted power (mW/cm2) or of the ultrasound instrument’s gain setting are changed 
(nor are biological different conditions of subjects examined). 
 Near wall measurements, however, are performed on ”far edge” principles, which 
means that IMT to some degree may be dependent on some of the technical conditions 
mentioned above (e.g., gain setting). Standardized examination conditions therefore are 
particularly important for the near wall measurements. It is, however, not possible, in 
technical terms, to obtain such ideal conditions because individually instrument adjusting 
alternatives always are more or less involved in processing optimal B-mode images. 
However, setting of functions such, as emitted power of ultrasound, preprocession, 
postprocession, gainsetting, etc. should be standardized as much as possible. Biologic 
inter-individual differences (obesity, position of the neck arteries, short or long necks, 
etc.) causing need of some different adjustments, however, are not possible to 
standardize. If the visibility of IMT and plaques is not optimal, the gainsetting (both the 
general and the segmental) should first be adjusted to improve the quality of the image. 
The gain should all the time be set high enough to identify soft, echolucent plaques but 
not too high to conceal small plaques due to “ultrasound noise”. Only as an exception, 
adjustments of the other functions should be done. 
   






12. Scoring of plaque-echogenicity. We aim at the highest echogenicity as possible since    
false too low echogenicity is a common problem due to several reasons: The plaque is cut 
too skew by the ultrasound beam, the longitudinal axis of the insonated vessel wall is not 
parallel to the ultrasound probe surface causing sub-optimal reflection of ultrasound 
energy (scattering), a far wall plaque is located within a ultrasound shadow from a 
calcified near wall plaque due to sub-optimal insonation angel. We therefore use the 
ultrasound signals from the media-adventitia interface as a reference of echogenicity to 
enhance precision on morphology scoring. This structure is easy to identify and is always 
presenting as high-echogenic, and is also localized close to the target, the atherosclerotic 
plaque. 
      In a 4-step scale from 1 to 4, the media-adventitia echogenicity and plaques of similar 
echogenicity is given a value of 4. On a grey-scale, such objects appear white or close to 
white. A plaque of grade 1 consequently reflects no or almost no ultrasound signals and 
appears black or dark grey on images. Flowing blood appearing black on ultrasound 
images is the reference structure on this end of the scale. Grade 2 and 3 represent 
intermediary echogenicity: grade 1, the plaque consisting of more echolucent than 
 echogenic material); grade 3, more echogenic than echolucent 
(> 50% echogenic material). Apart from the ultrasound reference structures used in this 
protocol, the echogenicity scoring is similar to previous reports in the literature.1, 2   
      Grade 5 represents plaques that are not possible to classify on ultrasound of technical 
reasons (e.g., plaques in the far wall concealed by the echo shadow from calcified near 
wall plaques, not possible to angling of the probe to obtain representative images, plaque 
localized to high upstream to get high-quality images, etc.) 
      When a plaque is heterogeneous and consists partly of high-echogenic and partly of 
low-echogenic material, the scoring of echogenicity is based of an overall impression of 
the dominating plaque echogenicity. When more than 80% of the plaque is of a given 
echogenicity, the echogenicity is scored as if the whole plaque consisted of this 
echogenicity although the rest of the plaque echogenicity was differing 2 or 3 grades from 
the dominating class of echogenicity. If the percentage is below 80%, interpolating is 
performed by judgement.  
 
 
     Thus, plaque echogenicity is classified as follows: 
   
 Grade 1: Echolucent  (0- 20 % of plaque material is high-echogenic). 
 Grade 2: Predominant echolucent (21-50 % of plaque material is high-echogenic). 
 Grade 3: Predominant echogenic (51-79 % of plaque material is high-echogenic). 
 Grade 4: Echogenic (80-100 % of plaque material is high-echogenic). 
 Grade 5: Missing, not classifiable 
 
    In the same way, a total echogenicity status for an artery is determined if more than one 
plaque is present. The same limit of 80% is the basis of scoring of total plaque area.  







13. Do not remove the cassette from the video recorder before the end of the day, or when the   
      cassette is full. 
 
14. Check that the registration form is completed appropriately. In the ”Remarks” box,    
      coding for reasons for missing of measurable images should be done:  
   
   MB 1= missing images from BULB due to obesity. 
   MB 2= missing images from BULB due to a steep angle between CCA and BULB. 
   MB 3= missing images from BULB due to technically difficult examinations. 
   MB 4= missing images from BULB due to previous surgery or radiation. 
   MB 5= other reasons 
   In the same way, missing coding for CCA and ICA is performed: MC 1, MC 2, etc.  
 
A referral form to Department of Neurology, University Hospital, Tromsø is completed when 
a suspected carotid stenosis or occlusion are found. Two criteria for defining a stenosis are 
used. Either a velocity increase across an atherosclerotic plaque in BULB of 0.1 m/sec. or 
more or 0.2 m/sec. in ICA, compared to the reference velocity distally in ICA; or a plaque 
thickness that constitutes 35% or more of the lumen diameter at the plaque site. The 
velocities should be manually angle-corrected for the angle at which Doppler-beams are 
emitted into the vessel. Occlusion is suspected when the open lumen of the artery is not 
visible on B-mode or if there is a visible occluding plaque in the artery, and there is no 
detectable flow in the artery by pulsed Doppler or by colour-Doppler. The referral threshold 
should be low to avoid false negative stenosis cases. The person, who is referred, should be 
given a written and verbal information of the finding and clinical implications before living 
the room.       
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(Digitizing plaque images from SVHS-cassette) 
 
 PC + monitor, and Panasonic 7560 video recorder + monitor are switched on. The 
video screen is preset to PAL. 
 
 The videocassette is inserted in the video recorder. Wind on to the plaque image of 
interest. Check continuously the plaque registration form (Excel-sheet) to ensure that 
no plaque images are missed. The frame on the video screen should be smoothly 
adjusted until it is stationary, without any “snow”.  
 
 Start Matrox Intellicam on the PC desktop. 
 
 If this is the first ‘grab’ from the videocassette, the GSM-value for the background 
colour of the recorded image should be calibrated according to the following 
procedure (1-5). If not, proceed to the next step. 
 
1. Grab an image (see the procedure for GRAB!). 
2. Save the image in the catalogue C:\My documents\Plaque\Test as test.tif. 
3. Export the image to Adobe Photoshop 3.0. 
4. Press the Image mode – Greyscale, and then ’OK’ on the mini-menu 
’Discard colour information?’ 
5. Delimit a ’black’ area outside the B-mode picture on the screen with the 
squared tool function, and press Image – Histogram. The mean value 
should be between 1-3. If it is <1 or  >3, the ’BLACK LEVEL’-button on 
the Panasonic 7650’s ’TBC CONTROL’ is turned a little 
clockwise/counter-clockwise respectively, and the procedure is repeated 
until the mean value is between 1-3 (but not 0, then the ’BLACK LEVEL’ 
is too low!). This procedure should be repeated at every start-up, and each 
time a new videocassette is inserted, to ensure that background-black really 
is black.  
 
GRAB! 
 Press Ctrl + M, or press the camera-icon in the menu (nr 6 from left) to grab the 
image. Repeat until you have an optimal image. Every time Matrox Intellicam is 
started, the ‘Digitizer Configuration Format’ menu will appear on the screen – Choose 
’PAL’ in the box and press ‘OK’.  
 
 Save the image by pressing Alt+F – A, or File – Save As, (but not Ctrl+S, or Alt+F 
– S, then the previous image will be erased!) and use the file name from the plaque 
registration form. PS – check for writing error. The file is saved in the catalogue 
corresponding to the tape number (Tape 01 etc…) under Tr4 or Tr5 respectively. (To 
simplify the file name routine, the file can be copied from Excel, and pasted in the file 
name column in Intellicam, and thereafter press <Enter> to save…but still check for 
writing error!!). Fill in ’grab’ – date (format: ddmmyy, f. ex 011102, 150103) on the 
Excel sheet as a ‘receipt’. 
 
 Wind on to the next plaque recording, adjust smoothly and repeat the 




 The participant’s personal code will appear on the upper left hand side of the screen, your 
“Carotid”
 







diameter of the artery. The ideal is that the “double line”
plaque both proximally and distally. The “double line” IMT should be detected in both the near and 
should be depicted horizontally on the screen so that the “double line” contour of the intima 
 
 Plaques in the CCA, in the bifurcation or the ICA with maximum thickness ≥50% 
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